Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Moderna (MRNA) posted quarterly Long-Term Deferred Tax of $81.0 million for Q3 2024, little changed on a QoQ basis from $81.0 million in Q2 2024.

Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024) Analysis & Trends

Moderna has reported Long-Term Deferred Tax for 4 years, with the latest figure at $81.0 million in Q3 2024.

Long-Term Deferred Tax for Q3 2024 came in at $81.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $81.0 million (changed N/A YoY), and the FY2023 annual result was $81.0 million, down 91.75% from the prior year.
Long-Term Deferred Tax steadied at $81.0 million in Q3 2024, from $81.0 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $1.5 billion in Q2 2023 and troughed at $50.0 million in Q1 2021.
A 4-year average of $485.5 million and a median of $203.5 million in 2021 frame the typical range for Long-Term Deferred Tax.
The widest annual swing landed in 2022, when Long-Term Deferred Tax surged 1089.39%; it then sank 94.53% in 2024.
A 4-year view of Long-Term Deferred Tax shows it stood at $326.0 million in 2021, then surged by 201.23% to $982.0 million in 2022, then plunged by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $81.0 million in Q3 2024, $81.0 million in Q2 2024, and $81.0 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Moderna	25.26 Bn	20.13 Bn	52.00 Mn

Download Data